Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Few treatment options exist for patients with myelofibrosis (MF), and their survival is significantly shortened. Activating mutation of the JAK2 tyrosine kinase (JAK2(V617F)) is found in approximately 50% of MF patients. CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Santos, Fabio P. S., Kantarjian, Hagop M., Jain, Nitin, Manshouri, Taghi, Thomas, Deborah A., Garcia-Manero, Guillermo, Kennedy, Debra, Estrov, Zeev, Cortes, Jorge, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081385/
https://ncbi.nlm.nih.gov/pubmed/20008298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-10-246363
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados